Recipharm & Synthonics Join Forces to Promote Delivery Technology
Recipharm Pharmaceutical Development AB and Synthonics, Inc. recently announced the formation of a Joint Promotion Agreement. The contract, the first of its kind to be entered into between the two companies, will provide Recipharm customers full access to Synthonics’ metal coordination chemistry, improving the delivery and performance of their compounds.
“We are pleased to partner with Synthonics to expand the services and solutions that we can offer our clients. The application of Synthonics’ chemistry improves important characteristics, such as bioavailability and solubility, and thus increases the likelihood that promising molecules will become viable products,” said Recipharm Pharmaceutical Development’s General Manager, Maria Lundberg. “Furthermore, our ability to offer such services through this novel partnership distinguishes us from other CDMOs.”
Ken Slepicka, CEO of Synthonics, added, “Synthonics is delighted to partner with Recipharm to help advance promising molecules to market. We are very impressed with Recipharm’s formulation and development teams and believe that our chemistry will fit well in their existing tool kit of solutions. We expect this agreement to help us reach new clients and to expand the use of our chemistry.”
Recipharm AB is a leading contract development and manufacturing organization (CDMO) based in Sweden employing some 1600 employees. The company operates development and manufacturing facilities in Sweden, France, the UK, Germany, and Spain and is headquartered near Stockholm. For more information, visit www.recipharm.com.
Synthonics, Inc. is a specialty pharmaceutical company focused on the discovery, development, and licensing of patent-protected drugs (metal coordinated pharmaceuticals or MCPs) that incorporate its proprietary metal coordination chemistry. MCPs have a profound effect on a variety of pharmacokinetic parameters, including improved absorption, reduced toxicity, more reliable dosing, modified release, and targeted delivery. For more information, visit www.synthonicsinc.com.
Total Page Views: 784
